Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018148 · ClinicalTrials.gov registry record · Phase 2
Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation
A Phase 2 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT00018148 is a Phase 2 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 158 participants.
The verdict
NCT00018148, a Phase 2 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.
Interventions
- DRUG transdermal nicotine
- DRUG nortriptyline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 1998-04 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00018148
The ClinicalTrials.gov registry entry for NCT00018148 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which transdermal nicotine is the first listed.
NCT00018148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00018148 about?
NCT00018148 is a clinical study titled "Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation". Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in whic...
What is the current status of trial NCT00018148?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 1998-04. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00018148?
The interventions under investigation include: transdermal nicotine (DRUG), nortriptyline (DRUG).
Who is sponsoring clinical trial NCT00018148?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.